Imugene Ltd · ASX:IMU

Imugene — Shareholder Meeting (November 2006)

14 slides from Imugene's shareholder meeting presentation, November 2006

  1. Slide 1: Animal Health Biological Products: 2006 Annual Review – Highlights & Update

    Slide 1: Animal Health Biological Products: 2006 Annual Review – Highlights & Update

    IMUGENE Animal Health Biological Products 2006 Annual Review – Highlights & Update November 2006 Dr Warwick Lamb Managing Director

  2. Slide 2: Product & Industry Focus

    Slide 2: Product & Industry Focus

    IMUGENE Product & Industry Focus • Biological animal health products • Proven & patented platform science • Advanced products with market demand & need • Strong product pipeline • Early licensing success • Early regulatory approvals

  3. Slide 3: Highlights: Poultry Productivity Enhancer

    Slide 3: Highlights: Poultry Productivity Enhancer

    Highlights Poultry Productivity Enhancer – Licensed to Merial in Oct 2005 – Completion of two Australian safety trials – Sign-up fees received & milestone payment recently earned – Progressing through product development for global and Australian commercial releases

  4. Slide 4: Highlights: Avian Influenza

    Slide 4: Highlights: Avian Influenza

    Highlights Avian Influenza – Two vaccine candidates completed • For broilers & layers/breeders – Fully lab tested – High quality trial site secured in US – Poultry trials to commence this quarter – Successful grant funding of $882,000 for product development – International interest

  5. Slide 5: Highlights: Coccidiosis

    Slide 5: Highlights: Coccidiosis

    Highlights Coccidiosis • Vaccine candidates completed • Final candidate verification underway • Expect to handover to Teva/Abic for poultry trials in early 2007 • Anticipate licensing FAV for delivery of these vaccines if successful in trials

  6. Slide 6: Highlights: Patents

    Slide 6: Highlights: Patents

    Highlights Patents • Successfully defended US interference proceedings for PAV • Improved patent position in US with patent assignment • Lodged new patent for PAV in US – Prolonged commercial protection • FAV patent granted in Europe

  7. Slide 7: Highlights: Imugene Laboratory

    Slide 7: Highlights: Imugene Laboratory

    Highlights Imugene Laboratory • Successfully established our own leasehold laboratory facility at La Trobe University • Significant improvement in scientific progress – both quality and timeframes • Focused commercial research • Marked improvement in product quality control

  8. Slide 8: Highlights: Regulatory

    Slide 8: Highlights: Regulatory

    Highlights Regulatory • New Imugene Institutional Biosafety Committee • Applications lodged for OGTR licences for PAV and FAV laboratory work • Intentional Release application for the Poultry Productivity Enhancer for final submission to OGTR

  9. Slide 9: Update: Pig Vaccines

    Slide 9: Update: Pig Vaccines

    Update Pig Vaccines • PAV-PRRS US trial site – Final negotiation phase • PAV-Merial product improvements • PAV pipeline – product dependent pathways

  10. Slide 10: Activity: 1st Half 2007

    Slide 10: Activity: 1st Half 2007

    Activity 1ST Half 2007 • Expanding Imugene’s animal health reputation in US and Europe • Further US based product trials • Advancing international commercial arrangements

  11. Slide 11: Activity – Poultry: 1st Half 2007

    Slide 11: Activity – Poultry: 1st Half 2007

    Activity – Poultry 1ST Half 2007 • Avian flu trial – To be completed Jan 2007 – Interim results – Jan 2007 – Full results – first quarter 2007 • Poultry Productivity Enhancer – Regulatory progress – OGTR – Product development funded by Merial • Coccidiosis – Vaccine constructs to be trialled by Teva

  12. Slide 12: Activity – Pigs: 1st Half 2007

    Slide 12: Activity – Pigs: 1st Half 2007

    Activity – Pigs 1ST Half 2007 • Pig vaccines – US based PRRS vaccine trial – Improved PAV-Merial vaccines constructed and delivered to Merial – Other PAV products developed for disease specific markets • PAV patents – International prosecution of new PAV patent

  13. Slide 13: Update: Financial Position

    Slide 13: Update: Financial Position

    Update Financial Position • Net cash outflow – $137k/mth = under budget • 2007 budget approx $150k/mth • Merial funding development work on Poultry Productivity Enhancer • $2.3m cash – Sep 06 • $880k Government grant for Bird Flu – 2 years • Financial returns from Merial licence • Contract payments

  14. Slide 14: Update: Corporate

    Slide 14: Update: Corporate

    Update Corporate • Directors & management – Graham Dowland – Chairman – Warwick Lamb – CEO – Roger Steinepreis – Director – Mike Sheppard – Chief Scientific Officer • Shares on issue 130 m (QIC – 5.7%, Board – 13%) • Options on issue – Expiry 31 Dec 06 (25c-30c) 6.2 m – Expiry 31 Jan 07 (50c) 4.5 m

Source: Internet Archive copy of imugene.com

More decks from Imugene Ltd

All 54 Imugene decks